---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005970"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:32:31.935435+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma to raise up to $4.5M via rights offering with SRO LLC backstop of $2.25M

## Summary
- Rights offering of up to $4.5M units: 1 share SHPH + 1 warrant ($2.35 strike) + equity stake in Shuttle Diagnostics.
- SRO LLC (affiliate of Boustead Securities CEO) commits $2.25M anchor purchase and backstop for unsold units up to additional $2.25M.
- Unit price at 90% of 5-day VWAP; proceeds to fund diagnostics lab for clinical trials toward FDA device approval.
- Boustead Securities receives $112,500 commitment fee, 8% commission on proceeds, plus $40,000 expenses.
- Rights offering contingent on SEC registration statement filing (Form S-1) and effectiveness; timing uncertain.

## SEC filing metadata
- accession: 0001493152-24-005970
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/0001493152-24-005970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005970
- JSON: https://secwatch.observer/filing/0001493152-24-005970.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005970.txt

## Key facts
- Material Agreements
  Shuttle Pharmaceuticals Holdings, Inc. entered into Purchase Agreement with SRO, LLC valued at $2,250,000 (effective 2024-02-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: SRO, LLC
  - Value: $2,250,000
  - Effective: 2024-02-07
  source text: Effective February 7, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“SHPH” or the “Company”), and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., a Maryland corporation (“Diagnostics”), entered into a securities purchase agreement (the “Purchase Agreement”) with SRO, LLC, a Nevada limited liability company (“SRO LLC”), pursuant to which SRO LLC agreed to commit to purchasing from the Company $2,250,000 of units (the “Units”) from the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/0001493152-24-005970-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.